$6.06-0.62 (-9.28%)
News25/Ratings0
Price$6.06-0.42 (-6.48%)
2026-01-212026-04-24
News · 26 weeks18-67%
2025-11-022026-04-26
Mix1190d
- SEC Filings9(82%)
- Other2(18%)
Latest news
25 items- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Leadership Update8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Other Events8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- PRAdvanced Biomed Inc. Announces 1 for 20 Share ConsolidationTainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company" or "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced a reverse stock split of the Company's issued and outstanding common stock at a ratio of 1 for 20 shares (the "Reverse Split"), which will take effect at the open of The Nasdaq Stock Market ("Nasdaq") on February 20, 2026. In accordance with Section 78.320.2 of the Nevada Revised Statutes, on January 12, 2026, the holders of a majority of the outstanding voting power of the Company approved by written co
- SECSEC Form 10-Q filed by Advanced Biomed Inc.10-Q - Advanced Biomed Inc. (0001941029) (Filer)
- PRAdvanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug DiscoveryTainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company", "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the "Agreement") with Chi‑Mei Medical Center to initiate a 120‑case feasibility study designed to evaluate the predictive accuracy of the Company's A+PerfusC™, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro. The feasibility study is a non‑interventional clinical resea
- SECAmendment: Advanced Biomed Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K/A - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form DEF 14C filed by Advanced Biomed Inc.DEF 14C - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form PRE 14C filed by Advanced Biomed Inc.PRE 14C - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- PRAdvanced Biomed Inc. Announces Disposal of its Hong Kong SubsidiaryTainan City, Taiwan, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company", "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced that on December 23, 2025, it entered into an agreement (the "Agreement") with an unrelated third party, Wei Ha Hui (the "Buyer"), pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed (HK) Limited, a Hong Kong company and a wholly owned subsidiary of the Company (the "Hong Kong Subsidiary"), for an aggregate purchase price of US$23,000 based on a valuatio
- SECSEC Form 10-Q filed by Advanced Biomed Inc.10-Q - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form NT 10-Q filed by Advanced Biomed Inc.NT 10-Q - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form 10-K filed by Advanced Biomed Inc.10-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form NT 10-K filed by Advanced Biomed Inc.NT 10-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)
- PRAdvanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company", "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the launch of its A+PerfusC™ system, a compact, all‑in‑one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro. (A+PerfusC™ 3D System-a perfusion-based 3D cell culture in a compact incubator) The A+PerfusC™ platform integrates automated perfusion with environmental control in a compact format that can be mounted directly onto a microscope for real‑time ob
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Advanced Biomed Inc. (0001941029) (Filer)
- SECSEC Form S-1 filed by Advanced Biomed Inc.S-1 - Advanced Biomed Inc. (0001941029) (Filer)
- SECAdvanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Advanced Biomed Inc. (0001941029) (Filer)